Buscar
Inovio Pharmaceuticals Inc
INOAñadir a la lista de seguimiento
1.220USD
+0.030+2.52%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
84.18MCap. mercado
PérdidaP/E TTM
Más Datos de Inovio Pharmaceuticals Inc Compañía
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Información de Inovio Pharmaceuticals Inc
Símbolo de cotizaciónINO
Nombre de la empresaInovio Pharmaceuticals Inc
Fecha de salida a bolsaDec 08, 1998
Director ejecutivoShea (Jacqueline Elizabeth)
Número de empleados134
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 08
Dirección660 W. Germantown Pike
CiudadPLYMOUTH MEETING
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19462
Teléfono18584103134
Sitio Webhttps://www.inovio.com/
Símbolo de cotizaciónINO
Fecha de salida a bolsaDec 08, 1998
Director ejecutivoShea (Jacqueline Elizabeth)
Ejecutivos de Inovio Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Inovio Pharmaceuticals Inc?
Los cinco principales accionistas de Inovio Pharmaceuticals Inc son: Dr. Jacqueline Elizabeth Shea, Ph.D.
¿Cuántas instituciones poseen acciones de Inovio Pharmaceuticals Inc (INO)?
A fecha de 2026Q1, 266 instituciones poseen acciones de Inovio Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 32.85M, lo que representa el 40.31% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 3035014.00.